NEW YORK, Feb. 16 (GenomeWeb News) - Amersham and Bayer's diagnostics division plan to co-develop assays and instrumentation for sequencing HIV and other infectious disease-causing pathogens, the companies said today.
Terms of the exclusive partnership call for Amersham to supply a modified version of its existing MegaBACE gene sequencer, and for Bayer to develop sequencing assay applications for the tool. Bayer will also buy Amersham's reagents and other consumables for these and "future assays," the companies said.
Amersham and Bayer plan to seek USregulatory approval for the instrument and assays. It was not immediately clear when the companies expect to commercialize the instrument or the assays.